SP1 and colorectal carcinoma: Thus, although inhibiting PKCζ represents an indirect strategy to interfere with the SP1/TEAD4 interaction and inhibit the oncogenic activity of YAP/TEAD, it may be infeasible to use PKCζ inhibitors for the treatment of YAP-active CRC.